JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Viatris Inc

Cerrado

SectorSalud

10.3 -0.68

Resumen

Variación precio

24h

Actual

Mínimo

10.3

Máximo

10.49

Métricas clave

By Trading Economics

Ingresos

3B

-4.6M

Ventas

328M

3.6B

Rentabilidad por dividendo

4.72

Margen de beneficio

-0.128

Empleados

32,000

EBITDA

2.9B

578M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+10.47% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

4.72%

2.33%

Próximas Ganancias

6 nov 2025

Fecha Próximo Dividendo

12 dic 2025

Próxima Fecha de Ex Dividendo

21 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.5B

12B

Apertura anterior

10.98

Cierre anterior

10.3

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

163 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Viatris Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 oct 2025, 09:10 UTC

Acciones populares

Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials -- WSJ

Comparación entre iguales

Cambio de precio

Viatris Inc Esperado

Precio Objetivo

By TipRanks

10.47% repunte

Estimación a 12 meses

Media 11.5 USD  10.47%

Máximo 15 USD

Mínimo 8 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Viatris Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

4 ratings

1

Comprar

2

Mantener

1

Vender

Puntuación técnica

By Trading Central

8.48 / N/ASoporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

163 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
help-icon Live chat